Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
  • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
  • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/736—Chitin; Chitosan; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
  • A61L24/08—Polysaccharides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/53—DNA (RNA) vaccination
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

• the invention described hereinafter relates to chitosan-conjugates with acidic chelate-complex forming agents, their crosslinked derivatives, the method of their manufacture and their use as a matrix having a variety of possible pharmaceu- tic, cosmetic and medical applications.
• EP-A-0 650 999 discloses chitosan adducts with acidic chelate forming agents.
• the viscosity of the resulting gels can be adjusted by the addition of salts of polyvalent metals and acids, in which chitosan is only moderately soluble or insoluble.
• JP-A-01239077 JAPIO-abstract No. 89-239077 discloses the addition of chitosan and ethylene diamine tetraacetic acid (EDTA) into fertilizers.
• EDTA ethylene diamine tetraacetic acid
• R represents a substituent selected from the group of -CH 2 COO " , -CH 2 CH 2 -N (-CH 2 COO ⁇ ) 2 and -CH 2 CH 2 -N ( -CH 2 COCf) -CH 2 CH 2 -N (-CH 2 COO " ) 2 .
• chitosan is reacted with EDTA in the presence of carbodiimides, i.e., by a carbodiimide mediated reaction.
• the negative ionic charge at the carboxylate group may be compensated by the respective positive charge provided by positively charged mono- or polyvalent counterions, such as protons, Li + , Na + , K + , Mg 2+ Ca 2+ , Zn 2+ and other positively charged inorganic or organic cations which may be represented by the cations to be complexed.
• positively charged mono- or polyvalent counterions such as protons, Li + , Na + , K + , Mg 2+ Ca 2+ , Zn 2+ and other positively charged inorganic or organic cations which may be represented by the cations to be complexed.
• the chitosan-conjugates according to the present invention are obtainable by reacting chitosan with an acidic chelate-complex forming agent (chelating agent) selected from the group of nitrilotriacetic acid (NTA) , ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA) in the presence of carbodiimides.
• chelating agent selected from the group of nitrilotriacetic acid (NTA) , ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA) in the presence of carbodiimides.
• the molar ratio of chitosan to chelating agents preferably is about 1:20 in case that no crosslinks should be present in the final product. In case that inter- and/or intramolecular crosslinking should be achieved the molar ratio of chitosan to chelating agent should be smaller than about 1:
• reaction is carried out in aqueous medium using l-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride as the mediator.
• the chelating agent is covalently linked to the chitosan-structure by the formation of an amide bond.
• chitosan-ethylenediarriinetetraacetate conjugates comprising the following substructure within their overall structures:
• compositions relate to pharmaceutical compositions, cosmetical compositions and bioadhesive matrices comprising the chitosan-conjugates described above.
• the chitosan-conjugates are comprised in a bioadhesive matrix which can be used for the manufacture of medicaments for the administration or delivery of drugs, preferably of peptide- or protein- containing active agents (drugs) .
• the chitosan-conjugates of the present invention and in particular the chitosan-EDTA-conjugate can be used as a bioadhesive matrix system for the administration of peptide and protein drugs, as gelling agent for semi-solid drug dosage forms and cosmetics and as a complexing polymer for mono- or polyvalent cations, preferably for pharmaceutic and/or cosmetic applications .
• conjugates according to the present invention Prior to using the conjugates according to the present invention for the final purpose as gelling agent, matrix, complexing agent, etc. it may be necessary to neutralize the carboxylic acid groups in the conjugate using a suitable alkaline agent.
• the present invention relates to chitosan- ethylenediamine tetraacetate conjugates.
• At least one of the carboxylic acid moieties of EDTA is bound to the amine moiety of chitosan to form an amide.
• EDAC l-ethyl-3- (3-dimethylaminopropyl) car- bodiimide hydrochloride
• the amount of EDTA covalently bound to chitosan can be controlled by the ratio of chitosan to EDTA employed.
• a preferred molar ratio of chitosan to EDTA is about 1:20 inter- and intramolecular crosslinking can be avoided.
• the chitosan-conjugates according to the present invention are not susceptible against alkaline media, i.e., pH-values >7.
• alkaline media i.e., pH-values >7.
• the present invention also relates to such crosslinked chitosan- conjugates containing intra- and/or intermolecular crosslinks. Said crosslinks are also formed by covalent amide bonds.
• the intra- and/or intermolecular crosslinking i.e., the crosslinking reaction between two polymers and/or within one polymer can also be carried out in the presence of a carbodiimide, i.e., by a carbodiimide-mediated reaction.
• the crosslinked chitosan-chelating agent conjugates according to the present invention are obtainable by reacting chitosan with the chelating agents described above at a molar ratio of chitosan to chelating agent of less than about 1:20, in the presence of a carbodiimide as described above.
• the inter- and/or intramolecular crosslinked chitosan-conjugate can be used for the same purpose as the (uncrosslinked) chitosan- conjugate as described above, but may have different properties in terms of complexing activity, viscosity, gelling properties, drug-releasing (delivering) properties, etc.
• the chitosan-conjugates or its crosslinked derivatives bearing the substructure defined above or in case of the crosslinked derivatives bearing a substructure containing more than one amide bond in the moiety stemming from the chelating agent will bind polyvalent cations, inhibit zinc proteases, and exhibit bioadhesive and gelling properties. It is possible to use the conjugates of the present invention in bioadhesive matrix systems, as gelling agents and complexing polymer for polyvalent cations in pharmaceutical and cosmetic applications.
• the inhibition of protease by the chitosan-conjugates of the invention and particularly of the chitosan-EDTA conjugates enables the administration of all kinds of pharmaceutically active agents such as peptide- and protein-containing drugs.
• the advantage is most significant in the administration of vaccines (antigens) , DNA and RNA.
• the bioadhesive carrier matrix according to the present invention allows the oral administration of active agents which can up to now only be administered par- enterally.
• the active agents are incorporated into the inventive matrix and are sufficiently protected against an enzymatic attack by, for instance, digestive enzymes and are released in a controlled manner, as described above.
• the chitosan-conjugates according to the present invention and in particular the chitosan-EDTA conjugates inhibit various digesting enzymes, such as zinc protease, they are capable of complexing polyvalent cations, they represent a readily hy- drated and strongly swelling gelling agent and they have bioadhesive properties.
• the fraction of re- sidual primary amine moieties at chitosan is 0.1% ⁇ 0.03%

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• Birds (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Materials Engineering (AREA)
• Biochemistry (AREA)
• Polymers & Plastics (AREA)
• Inorganic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Surgery (AREA)
• Dermatology (AREA)
• Cosmetics (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=3480978

Family Applications (1)

Country Status (3)

Families Citing this family (9)

• 1997
  • 1997-01-21 AT AT0007997A patent/ATA7997A/de not_active Application Discontinuation
• 1998
  • 1998-01-21 EP EP98907971A patent/EP0954537A2/de not_active Withdrawn
  • 1998-01-21 WO PCT/EP1998/000320 patent/WO1998031712A2/en not_active Ceased

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events